
## Chunyan Gu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1153177/publications.pdf Version: 2024-02-01



CHUNVAN CU

#	Article	IF	CITATIONS
1	Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy, 2021, 6, 78.	7.1	183
2	Review on circular RNAs and new insights into their roles in cancer. Computational and Structural Biotechnology Journal, 2021, 19, 910-928.	1.9	173
3	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. Journal of Hematology and Oncology, 2021, 14, 54.	6.9	75
4	Iron metabolism and its contribution to cancer (Review). International Journal of Oncology, 2019, 54, 1143-1154.	1.4	60
5	Research Advances on Acupuncture Analgesia. The American Journal of Chinese Medicine, 2020, 48, 245-258.	1.5	49
6	Insights into a Crucial Role of TRIP13 in Human Cancer. Computational and Structural Biotechnology Journal, 2019, 17, 854-861.	1.9	42
7	Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer. , 2022, 234, 108123.		37
8	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Molecular Cancer, 2021, 20, 84.	7.9	33
9	BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. Signal Transduction and Targeted Therapy, 2021, 6, 361.	7.1	27
10	NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma. Acta Pharmaceutica Sinica B, 2022, 12, 3313-3325.	5.7	27
11	ZiBuPiYin recipe improves cognitive decline by regulating gut microbiota in Zucker diabetic fatty rats. Oncotarget, 2017, 8, 27693-27703.	0.8	24
12	BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. Medical Oncology, 2015, 32, 81.	1.2	21
13	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer, 2018, 18, 1152.	1.1	21
14	Chromosomal instability and acquired drug resistance in multiple myeloma. Oncotarget, 2017, 8, 78234-78244.	0.8	21
15	YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis. Oncogene, 2022, 41, 1482-1491.	2.6	21
16	A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. Journal of Experimental and Clinical Cancer Research, 2022, 41, 85.	3.5	21
17	Deciphering bacterial community changes in zucker diabetic fatty rats based on 16S rRNA gene sequences analysis. Oncotarget, 2016, 7, 48941-48952.	0.8	19
18	Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer Journal, 2018, 8, 22.	2.8	15

Chunyan Gu

#	Article	IF	CITATIONS
19	<p>Bioactive Compounds from <em>Abelmoschus manihot L</em>. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment</p> . OncoTargets and Therapy, 2020, Volume 13, 959-973.	1.0	15
20	An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. American Journal of Physiology - Renal Physiology, 2016, 311, F852-F863.	1.3	14
21	AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 11.	3.5	14
22	Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death and Disease, 2021, 12, 206.	2.7	13
23	Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1501.	1.3	11
24	Splicing factor arginine/serineâ€rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosomeâ€based cellular communication. Clinical and Translational Medicine, 2022, 12, e684.	1.7	9
25	CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. Journal of Hematology and Oncology, 2021, 14, 90.	6.9	8
26	Lycium barbarum polysaccharides attenuate rat anti-Thy-1 glomerulonephritis through mediating pyruvate dehydrogenase. Biomedicine and Pharmacotherapy, 2019, 116, 109020.	2.5	7
27	RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia, 2021, 35, 1803-1807.	3.3	7
28	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. Oncotarget, 2017, 8, 56858-56867.	0.8	7
29	HUANGKUISIWUFANG inhibits pyruvate dehydrogenase to improve glomerular injury in anti-Thy1 nephritis model. Journal of Ethnopharmacology, 2020, 253, 112682.	2.0	5
30	Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2021, 9, 675939.	1.8	3
31	Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine. Frontiers in Oncology, 2021, 11, 779562.	1.3	3
32	RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma. Blood, 2019, 134, 3068-3068.	0.6	0
33	The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma. Blood, 2019, 134, 5586-5586.	0.6	0
34	CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion. Blood, 2020, 136, 9-10.	0.6	0